Cancer detection has shifted from symptom-based diagnosis to proactive, personalized screening using advanced technologies, allowing earlier and more accurate detection, especially for high-risk patients and hard-to-detect cancers.
High-risk gastric cancer screening focuses on individuals with family history, hereditary syndromes like Lynch syndrome, pre-cancerous stomach conditions, or origins from regions with high gastric cancer rates. Upper endoscopy remains the main tool, letting doctors visually inspect the stomach lining and take biopsies. Researchers are also exploring blood-based biomarkers to identify who should undergo endoscopy, making screening more personalized and cost-effective.
Blood-based breast cancer detection, or liquid biopsy, detects tumor DNA, cells, or proteins in the bloodstream. Already FDA-approved for managing advanced breast cancer, these minimally invasive tests may help track treatment response, detect resistance, and provide early warning. Ongoing research aims to use liquid biopsies for early detection, complementing mammography and potentially enabling annual multi-cancer screening. These innovations are paving the way for proactive, patient-focused cancer care.